# Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

> **NCT00070382** · PHASE3 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Anemia
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Multiple Myeloma and Plasma Cell Neoplasm
- Precancerous/Nonmalignant Condition
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** darbepoetin alfa
- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00070382
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2003-11
- **Final completion:** —
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070382, "Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00070382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*